Retrospective Cohort Study
Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Jul 27, 2024; 16(7): 995-1008
Published online Jul 27, 2024. doi: 10.4254/wjh.v16.i7.995
Table 1 Follow up schedule of enrolled chronic hepatitis B patients, Harar, Eastern Ethiopia
Laboratory test On treatment Not on treatment After 4 weeks CBC, ALT, AST, creatinine Every 3 months CBC, ALT, AST, creatinine HIV rapid test CBC, ALT, AST, creatinine Every 6 months HBsAg, HBV DNA viral load, HBeAg/anti-HBe (only if HBeAg-positive previously) HBsAg, HBV DNA viral load Every 12 months Abdominal ultrasound as screening for HCC
Table 2 Baseline characteristics of patients with chronic hepatitis B, by cirrhosis status, Harar, Eastern Ethiopia
Variable All patients, n = 193 No cirrhosis, n = 133 Cirrhosis, n = 60 P valueSex, n (%) 0.020a Male 132 (68.4) 84 (63.2) 48 (80.0) Female 61 (31.6) 49 (36.8) 12 (20.0) Age group by years, n (%) 0.852 18-25 69 (35.8) 47 (35.3) 22 (36.7) 26-35 70 (36.3) 47 (35.3) 23 (38.3) 36-45 36 (18.7) 18 (13.5) 18 (30.0) > 45 18 (9.3) 14 (10.5) 4 (6.7) Marital status1 , n (%) 0.597 Single 61 (31.6) 45 (33.8) 16 (26.6) Married 123 (63.7) 81 (60.9) 42 (70.0) Divorced/widowed 3 (1.6) 2 (1.5) 1 (1.7) Address, n (%) 0.032a Harar 48 (24.9) 40 (30.0) 8 (13.3) Dire Dawa 56 (29.0) 42 (31.6) 14 (23.3) Oromia 71 (36.8) 34 (25.6) 37 (61.7) Somali 18 (9.3) 17 (12.8) 1 (1.7) Occupation2 , n (%) 0.009a Farmer 33 (17.1) 14 (10.5) 19 (31.7) Housewife 29 (15.0) 22 (16.5) 7 (11.7) Student 23 (11.9) 14 (10.5) 9 (15.0) Public servant 31 (16.1) 26 (19.5) 5 (8.3) Self employed 18 (9.3) 12 (9.0) 6 (10.0) Others 19 (9.8) 14 (10.5) 5 (8.3) Family history of liver cancer3 , n (%) 0.569 No 183 (94.8) 125 (93.9) 58 (96.7) Yes 9 (4.7) 7 (5.3) 2 (3.3) Traditional herbal medicine4 , n (%) 0.220 No 169 (87.6) 120 (90.2) 49 (81.7) Yes 21 (10.9) 11 (8.3) 10 (16.7) Pregnant5 , n (%) 0.085 No 51 (89.4) 39 (86.7) 12 (100) Yes 6 (10.5) 6 (13.3) 0 Breast feeding, n (%) 0.110 No 54 (94.7) 43 (95.6) 11 (91.7) Yes 3 (5.3) 2 (4.4) 1 (8.3) Alcohol abuse, n (%) 0.172 No 158 (81.9) 105 (78.9) 53 (88.3) Yes 35 (18.1) 28 (21.1) 7 (11.7) Khat abuse, n (%) 0.001a No 88 (45.6) 71 (53.4) 17 (28.3) Yes 105 (54.4) 62 (46.6) 43 (71.7)
Table 3 Clinical presentation of patients with chronic hepatitis B, by cirrhosis status, Harar, Eastern Ethiopia
Variables All patients, n = 193 No cirrhosis, n = 133 Cirrhosis, n = 60 P valueSymptoms, n (%) 69 (35.8) 58 (43.6) 57 (95.0) < 0.001a Jaundice 34 (17.6) 14 (10.5) 20 (33.3) 0.001a Abdominal pain 69 (35.8) 38 (28.6) 31 (51.7) 0.003a Abdominal swelling 57 (29.5) 20 (15) 37 (61.7) < 0.001a Edema 32 (16.6) 6 (4.5) 26 (43.3) < 0.001a Nausea/vomiting 36 (18.7) 13 (9.8) 23 (38.3) < 0.001a Hematemesis 24 (12.4) 8 (6.0) 16 (26.7) < 0.001a Pruritus 18 (9.3) 10 (7.5) 8 (13.3) 0.199 Muscle/joint aches 44 (22.8) 21 (15.8) 23 (38.3) 0.001a Confusion 13 (6.7) 9 (6.8) 4 (6.7) 0.979 Weight loss 51 (26.4) 18 (13.5) 33 (55.0) < 0.001a Signs, n (%) BMI < 18.5 kg/m2 34 (17.6) 6 (4.5) 49 (81.7) < 0.001a Edema 30 (15.5) 18 (13.5) 12 (20.0) 0.033a Jaundice 12 (6.2) 0 (0) 12 (20.0) < 0.001a Pale conjunctiva 10 (5.2) 1 (0.8) 9 (15.0) < 0.001a Palmar erythema 14 (7.3) 2 (1.5) 12 (20.0) < 0.001a Gynecomastia 8 (4.1) 0 (0) 8 (13.3) 0.011a Ascites 29 (15.0) 0 (0) 29 (48.3) < 0.001a Splenomegaly 34 (17.6) 1 (0.8) 33 (55.0) < 0.001a Ultrasound findings1 , n (%) Normal liver surface 64 (47.8) 62 (80.5) 2 (3.5) 0.022a Mild uneven liver surface 11 (8.2) 5 (6.5) 6 (10.5) 0.478 Nodular and irregular surface 49 (36.6) 0 (0) 49 (86.0) < 0.001a Other 10 (7.5) 10 (13.0) 0 (0) 0.057
Table 4 Baseline biochemical, serologic, and virological data of patients with chronic hepatitis B, by cirrhosis status, Harar, Eastern Ethiopia
Variables All patients, n = 193 No cirrhosis, n = 133 Cirrhosis, n = 60 P valueWBC as 106 /L 5.9 (4.1-7.7) 6.5 (4.9-7.8) 4.2 (3.0-6.3) <0.001a Hemoglobin in g/L 14.7 (12.4-16.6) 15.5 (13.8-16.9) 11.8 (10.0-15.2) < 0.001a Platelet count as 109 /L1 <0.001a Median (IQR) 218 (119-294) 253 (184-344) 118 (54-180.3) < 150, n (%) 60 (32.1) 20 (15.7) 40 (66.7) ≥ 150, n (%) 127 (67.9) 107 (84.3) 20 (33.3) ALT (U/L)2 0.033a Median (IQR) 36 (23-58) 35 (22-52) 45 (27-84) < 40, n (%) 96 (52.5) 70 (55.6) 26 (45.6) ≥ 40, n (%) 87 (47.5) 56 (44.4) 31 (54.4) AST as IU/L3 0.016a Median (IQR) 40 (29-65) 36 (28-57) 51 (34-81) < 40, n (%) 90 (49.5) 67 (53.6) 23 (40.4) ≥ 40, n (%) 92 (50.5) 58 (46.4) 34 (59.6) Creatinine in mg/dL4 0.750 Median (IQR) 0.8 (0.6-1.0) 0.8 (0.6-1.0) 0.8 (0.6-1.0) ≤ 1.2, n (%) 150 (90.4) 101 (91.0) 49 (89.1) > 1.2, n (%) 16 (9.6) 10 (9.0) 6 (10.9) APRI score5 < 0.001a Median (IQR) 0.52 (0.29-1.35) 0.38 (0.26-0.70) 1.53 (0.66-2.84) < 1.5, n (%) 136 (77.7) 108 (91.5) 28 (49.1) ≥ 1.5, n (%) 39 (22.3) 10 (8.5) 29 (50.9) FIB-4 score6 < 0.001a Median (IQR) 1.06 (0.60-1.98) 0.85 (0.55-1.41) 1.93 (1.03-4.08) ≤ 3.25, n (%) 142 (82.6) 106 (90.6) 36 (65.5) > 3.25, n (%) 30 (17.4) 11 (9.4) 19 (34.5) HBeAg7 0.001a Negative, n (%) 105 (78.9) 80 (87.9) 25 (59.5) Positive, n (%) 28 (21.1) 11 (12.8) 17 (40.5) HBV viral load in IU/mL8 < 0.001a Median (IQR) 677 (135-7580) 486 (105-2863) 2843 (313-805407) < 2000, n (%) 114 (64.4) 91 (72.2) 23 (45.1) 2000-19999, n (%) 24 (13.6) 15 (11.9) 9 (17.6) ≥ 20000, n (%) 39 (22.0) 20 (15.9) 19 (37.3)
Table 5 Factors associated with cirrhosis among patients with chronic hepatitis B, Harar, Eastern Ethiopia
Baseline variables No cirrhosis, n = 133 Cirrhosis, n = 60 Bivariable Multivariable COR (95%CI) P valueAOR (95%CI) P valueSex, n (%) 0.022 0.308 Female 49 (36.8) 12 (20.0) 1 1 Male 84 (63.2) 48 (80.0) 2.33 (1.13-4.81) 1.74 (0.72-4.20) Age group by years, n (%) 0.635 < 40 100 (75.2) 47 (78.3) 1 ≥ 40 33 (24.8) 13 (26.7) 0.84 (0.40-1.74) Alcohol abuse, n (%) 0.122 No 105 (78.9) 53 (88.3) 1 Yes 28 (21.1) 7 (11.7) 0.49 (0.20-1.21) Khat abuse, n (%) 0.002 0.003a No 71 (53.4) 17 (28.3) 1 1 Yes 62 (46.6) 43 (71.7) 2.89 (1.50-5.59) 2.86 (1.44-5.68) ALT in U/L1 , n (%) 0.213 < 40 70 (55.6) 26 (45.6) 1 ≥ 40 56 (44.4) 31 (54.4) 1.49 (0.79-2.79) AST in U/L2 , n (%) 0.099 < 40 67 (53.6) 23 (40.4) 1 ≥ 40 58 (46.4) 34 (59.6) 1.71 (0.91-3.22) HBeAg3 , n (%) 0.007 0.022a Negative 80 (87.9) 25 (59.5) 1 1 Positive 11 (12.8) 17 (40.5) 3.61 (1.41-9.21) 3.81 (1.21-11.98) HBV viral load in IU/mL4 , n (%) 0.001 0.004a < 2000 91 (79.8) 23 (45.1) 1 1 ≥ 2000 35 (20.2) 28 (54.9) 3.17 (1.61-6.23) 5.29 (1.72-16.33)